Preparation and Bioavailability of Sustained-Release Doxofylline Pellets in Beagle Dogs
Authors:
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 34 (7) , 676-682
Abstract
The objective of this study was to develop doxofylline-loaded sustained-release pellets coated with Eudragit® NE30D alone (F1) or blend of Eudragit® RL30D/RS30D (F2) and further evaluate their in vitro release and in vivo absorption in beagle dogs. Doxofylline-loaded cores with a drug loading of 70% (w/w) were prepared by layering drug-MCC powder onto seed cores in a centrifugal granulator and then coating them with different kinds of polymethacrylates in a bottom-spray fluidized bed coater. Dissolution behaviour of these formulations was studied in vitro under various pH conditions (from pH 1.2 to pH 7.4) to evaluate the effect of pH on drug release profiles. It was found that F2 produced a better release profile than F1 did and two different release mechanisms were assumed for F1 and F2, respectively. The relative bioavailability of the sustained-release pellets was studied in six beagle dogs after oral administration in a fast state using a commercially available immediate release tablet as a reference. Coated with Eudragit® NE30D and a blend of Eudragit® RL30D/RS30D (1:12), at 5% and 8% coating level, respectively, the pellets acquired perfect sustained-release properties and good relative bioavailability, with small fluctuation of drug concentration in plasma. But combined use of mixed Eudragit® RL30D/RS30D polymers with proper features as coating materials produced a longer Tmax, a lower Cmax and a little higher bioavailability compared to F1 (coated with Eudragit® NE30D alone). The Cmax, Tmax and relative bioavailability of F1 and F2 coated pellets were 15.16 μg/ml, 4.17 h, 97.69% and 11.41 μg/ml, 5 h, 101.59%, respectively. Also a good linear correlation between in vivo absorption and in vitro release was established for F1 and F2, so from the dissolution test, formulations in vivo absorption can be properly predicted.Keywords
This publication has 14 references indexed in Scilit:
- Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pelletsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2006
- Production of an Extremly Low Dose Procaterol HCl Preparation by Fluidized-Bed Coating Method: In Vitro and In Vivo EvaluationDrug Development and Industrial Pharmacy, 2006
- Evaluation ofin-vitro dissolution andin-vivo absorption for two different film-coated pellets of clarithromycinArchives of Pharmacal Research, 2005
- The influence of Surelease and sodium alginate on the in-vitro release of tamsulosin hydrochloride in pellet dosage formJournal of Pharmacy and Pharmacology, 2005
- Impact of release characteristics of sinomenine hydrochloride dosage forms on its pharmacokinetics in beagle dogsWorld Journal of Gastroenterology, 2005
- Influence of Eudragit® NE 30 D Blended with Eudragit® L 30 D-55 on the Release of Phenylpropanolamine Hydrochloride from Coated PelletsDrug Development and Industrial Pharmacy, 2003
- Influence of Film Additives on Stabilizing Drug Release Rates from Pellets Coated with Acrylic PolymersPharmaceutical Development and Technology, 2001
- In Vitro Release Study of Transdermal Delivery Systems of ProgesteroneDrug Development and Industrial Pharmacy, 1998
- Preparation of Core Particles for Aqueous Film Coating Using Agitation Fluidized Bed.Chemical and Pharmaceutical Bulletin, 1997
- Mechanisms of Release from Coated Pellets1994